Insight Molecular Diagnostics Inc. Common Stock (IMDX) Stock Price

IMDXStock

$3.01−34.92%52W

Market Cap$98.50M

P/E—

PEG Ratio—

Div yield—

Beta1.87

IMDX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-26.53%

Price vs S&P 500 (4W)-23.61%

VGM Score30.09

Book Value / Share (Quarterly)$0.04

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)61.65%

Cash Flow / Share (Quarterly)$-0.95

Price vs S&P 500 (YTD)-71.79%

Gross Margin (TTM)48.32%

Net Profit Margin (TTM)-2955.63%

EPS (TTM)$-1.49

10-Day Avg Trading Volume0.27M

EPS Excl Extra (TTM)$-1.49

Revenue Growth (5Y)27.15%

EPS (Annual)$-1.65

ROI (Annual)-108.54%

Gross Margin (Annual)56.67%

Net Profit Margin (5Y Avg)-3363.86%

Cash / Share (Quarterly)$0.54

Revenue Growth QoQ (YoY)-53.86%

ROA (Last FY)-194.99%

Revenue Growth TTM (YoY)-60.77%

EBITD / Share (TTM)$-1.42

ROE (5Y Avg)-110.62%

Operating Margin (TTM)-3011.86%

Cash Flow / Share (Annual)$-0.88

P/B Ratio89.71x

P/B Ratio (Quarterly)787.10x

Net Income / Employee (Annual)$-913,100

EV / Revenue (TTM)48.81x

Net Interest Coverage (TTM)-459.75x

ROA (TTM)-141.47%

EPS Incl Extra (Annual)$-1.65

Current Ratio (Annual)1.27x

Quick Ratio (Quarterly)1.82x

3-Month Avg Trading Volume0.24M

52-Week Price Return-34.92%

Revenue / Employee (TTM)$30,400

P/S Ratio (Annual)24.29x

Asset Turnover (Annual)0.16x

52-Week High$8.51

Operating Margin (5Y Avg)-2088.66%

EPS Excl Extra (Annual)$-1.65

CapEx CAGR (5Y)20.96%

26-Week Price Return-16.62%

Quick Ratio (Annual)1.11x

13-Week Price Return-36.50%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.00x

Enterprise Value$81.51M

Revenue / Share Growth (5Y)-18.63%

Asset Turnover (TTM)0.05x

Revenue / Employee (Annual)$73,700

Pretax Margin (Annual)-1238.52%

Cash / Share (Annual)$0.40

3-Month Return Std Dev90.11%

Gross Margin (5Y Avg)37.19%

Net Income / Employee (TTM)$-897,400

ROE (Last FY)-108.54%

Net Interest Coverage (Annual)-502.66x

EPS Basic Excl Extra (Annual)$-1.65

Receivables Turnover (TTM)4.74x

Total Debt / Equity (Quarterly)0.92x

EPS Incl Extra (TTM)$-1.49

Receivables Turnover (Annual)2.96x

ROI (TTM)-374.15%

P/S Ratio (TTM)58.98x

Pretax Margin (5Y Avg)-2091.79%

Revenue / Share (Annual)$0.13

Price vs S&P 500 (52W)-50.45%

Year-to-Date Return-59.87%

5-Day Price Return-5.05%

EPS Normalized (Annual)$-1.65

ROA (5Y Avg)-103.60%

Net Profit Margin (Annual)-1238.52%

Month-to-Date Return-16.16%

EBITD / Share (Annual)$-1.61

Operating Margin (Annual)-1260.76%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-106.68%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.49

Inventory Turnover (TTM)1.92x

Pretax Margin (TTM)-2955.63%

Price vs S&P 500 (13W)-39.18%

Beta1.87x

Revenue / Share (TTM)$0.05

ROE (TTM)-426.68%

52-Week Low$2.42

vGradeF

gGradeD

mGradeC

vgmGradeD

IMDX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.23	-$0.24	-6.17%(-$0.01)
Q1 2026	May 13, 2026	-$0.26	-$0.12	+54.29%(+$0.14)
Q4 2025	Mar 26, 2026	-$0.24	-$0.72	-203.16%(-$0.48)
Q3 2025	Nov 10, 2025	-$0.24	-$0.23	+2.75%(+$0.01)
Q2 2025	Aug 11, 2025	-$0.24	-$0.30	-25.00%(-$0.06)

IMDX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.90

3.91

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	59.0x	-60.8%	48.3%	—	$3.01
IDXXIdexx Laboratories Inc	D	B	B	9.7x	12.8%	62.5%	14.3%	$560.36
LNTHLantheus Holdings, Inc	C	B	B	4.2x	2.4%	61.0%	40.7%	$99.70
NEOGNeogen Corp	C	C	A	2.9x	-0.3%	47.4%	—	$11.81
CLDXCelldex Therapeutics, Inc	F	F	C	13683.0x	-97.3%	17.6%	—	$27.53
NTLAIntellia Therapeutics, Inc	D	D	C	26.9x	12.6%	—	—	$11.42
QDELQuidelOrtho Corporation Common Stock	C	C	C	0.3x	-2.5%	44.6%	—	$12.91
ACHVAchieve Life Sciences, Inc.	F	F	B	36.8x	-89.3%	—	—	$6.38
MYGNMyriad Genetics Inc	C	C	D	0.5x	-3.2%	68.8%	—	$3.98
TKNOAlpha Teknova, Inc. Common Stock	D	C	B	8.7x	12.3%	34.6%	—	$7.08
NNNNAnbio Biotechnology Class A Ordinary Shares	F	C	F	34.0x	-5.7%	89.0%	—	$3.13
ICCCImmucell Corp	C	C	A	3.2x	8.5%	40.3%	—	$10.75
BMRABIOMERICA INC	B	D	B	1.9x	-16.2%	8.1%	—	$1.85
TRIBTrinity Biotech plc	B	D	C	0.1x	-16.6%	32.9%	—	$8.03
VNRXVolitionRx Limited	B	B	F	2.0x	86.3%	—	—	$0.18
CDIOCardio Diagnostics Holdings Inc. Common stock	—	D	C	345.9x	-25.9%	—	—	$1.69
QCLSQ/C Technologies, Inc. Common Stock	B	—	F	5.3x	—	24.7%	—	$0.54
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	F	156.9x	96.4%	62.0%	—	$1.45
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	F	—	—	—	—	$0.01

About Insight Molecular Diagnostics Inc. Common Stock

Insight Molecular Diagnostics is a molecular diagnostics company that uses donor-derived cell-free DNA (dd-cfDNA) quantification technology for transplant monitoring and related applications. The company markets GraftAssureIQ, a research-use-only test kit, and is developing GraftAssureDx, a clinical-grade product for broader adoption. Its mission is to democratize access to advanced molecular diagnostic testing to improve patient outcomes.